Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients

1. Avet-Loiseau, H.
2. Bahlis, N.J.
3. Chng, W.-J.
4. Masszi, T.
5. Viterbo, L.
6. Pour, L.
7. Ganly, P.
8. Palumbo, A.
9. Cavo, M.
10. Langer, C.
11. Pluta, A.
12. Nagler, A.
13. Kumar, S.
14. Ben-Yehuda, D.
15. Rajkumar, S.V.
16. San-Miguel, J.
17. Berg, D.
18. Lin, J.
19. Van De Velde, H.
20. Esseltine, D.-L.
21. di Bacco, A.
22. Moreau, P.
23. Richardson, P.G.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1182/BLOOD-2017-06-791228 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus